Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Braze Inc (BRZE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Braze Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Braze Inc trades at $25.26 (market cap $2.83B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 14.1× Braze Inc's market cap, and Braze Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BRZE | |
|---|---|---|
Market Cap | $39.89B | $2.83B |
Sector | Health | Technology |
52-Week High | $491.22 | $36.19 |
52-Week Low | $278.09 | $15.79 |
Enterprise Value | $38.15B | $2.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Braze (BRZE) trades at $25.13, up 1.17% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth, reaching $593.41M in 2025, but remains unprofitable with a net income margin of -15.51%. Recent news highlights accelerated growth and AI-driven product enhancements, such as new agentic AI capabilities announced on April 23, 2026.
The investment outlook is positive, driven by analyst consensus with a $34.78 price target and 96% buy ratings. Key opportunities include sustained revenue acceleration and AI adoption, while risks involve persistent losses and competitive pressures in the customer engagement software sector. Cash flow improvements in 2025 provide a foundation, but profitability remains a critical hurdle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →
